Abiomed's slows patient enrolment in artificial heart trial:
This article was originally published in Clinica
Abiomed, of Danvers, Massachusetts, has said that despite slowing the rate of patient enrolment for a human trial of its fully-implantable artificial heart, AbioCor, the firm expects to seek FDA approval for the device by the end of 2003. The delay in enrolment is reported to be due to Abiomed focusing on identifying and addressing potential problems in order to maximise the clinical success with the nine remaining AbioCor devices awaiting implantation.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.